Early efficacy of the ketogenic diet is not affected by initial body mass index percentile

Shastin Shull1, Gloria Diaz-Medina2, Lily Wong-Kisiel3

  • 1Mayo Medical School, Mayo Clinic, Rochester, Minnesota.

Pediatric Neurology
|March 25, 2014
PubMed

Insights

Initial body mass index and weight percentile do not impact the early success of the ketogenic diet for treating pediatric intractable epilepsy. This finding suggests that weight status at initiation does not predict treatment efficacy in children.

Area of Science:

  • Neurology
  • Pediatrics
  • Nutritional Science

Background:

  • Predictors of ketogenic diet success in pediatric intractable epilepsy remain unclear.
  • Understanding factors influencing treatment efficacy is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To investigate the impact of initial body mass index (BMI) and weight percentile on the early efficacy of the ketogenic diet.
  • To determine if baseline weight status affects seizure reduction in children with intractable epilepsy.

Main Methods:

  • Retrospective analysis of 48 children initiating the ketogenic diet between 2001-2010.
  • BMI (≥2 years) or weight percentile (<2 years) and seizure frequency at baseline and one month were recorded.
  • Responders defined as >50% seizure reduction; analysis of correlation and association with weight parameters.

Main Results:

  • No significant correlation found between initial BMI/weight percentile and one-month seizure frequency reduction.
  • No significant association observed between BMI/weight percentile quartiles and responder rates.
  • Overweight/obese children (BMI/weight percentile ≥85) showed similar responder rates compared to those <85 (6/14 vs 19/34).

Conclusions:

  • Higher initial BMI and weight-for-age percentiles do not negatively influence the ketogenic diet's efficacy.
  • Weight status at the initiation of the ketogenic diet is not a predictor of early treatment success in pediatric intractable epilepsy.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Metabolic States of the Body: Fasting and Starvation01:24

Metabolic States of the Body: Fasting and Starvation

During the initial hours of fasting, the body uses up its glycogen stores as an energy source. Once these glycogen reserves are depleted, the body begins breaking down stored triglycerides and structural proteins. During this stage, glycerol becomes a key substrate for gluconeogenesis, while free fatty acids undergo beta-oxidation to provide energy for tissues, such as skeletal muscle. In the fasting state, the body spares protein breakdown as much as possible to conserve muscle and structural...
2.8K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K